Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Isotype control overlays. by Chen Lu (135200)

“…<div><p>Decompression sickness is a fatal disease worldwide. Therefore, to find a prophylactic modality for decompression sickness is urgently required. …”

Original uncropped blot. by Chen Lu (135200)

“…<div><p>Decompression sickness is a fatal disease worldwide. Therefore, to find a prophylactic modality for decompression sickness is urgently required. …”

Raw Data. by Chen Lu (135200)

“…<div><p>Decompression sickness is a fatal disease worldwide. Therefore, to find a prophylactic modality for decompression sickness is urgently required. …”

Identification of BM-MSCs. by Chen Lu (135200)

Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

Comparison of ν_s measured and predicted estimates of the optimized GPR approach for (a) training, (b) validation, and (c) testing datasets. by Fahd Saeed Alakbari (10701871)

Digital Microfluidic Platform Based on Printed Circuit Board for Affinity Evaluation of Mertansine Aptamers by Dongliu Xiang (10688647)

“…Compared with manual methods, the digital microfluidic platform not only reduced the time for a single determination from 105 to 45 min but also significantly decreased the reagent consumption from 1280 to 30.72 μL. …”

Supplementary Material for: Significant Dry Weight Reduction After Transition from Peritoneal Dialysis to Hemodialysis by Lin Y.-T. (17065287)

“…After transitioning to HD, body weight decreased significantly, with a reduction of -2.8 kg at one month, -5.3 kg at three months, and -7.5 kg one year post-transition. …”

Table 1_Microglial adenosine A2A receptor in the paraventricular thalamic nucleus regulates pain sensation and analgesic effects independent of opioid and cannabinoid receptors.doc... by Yiping Cao (1229856)

“…Pharmacological activation of local PVT A_2AR with its agonist CGS21680 induced significantly decreased 50% paw withdrawal threshold (50%PWTs) and paw withdrawal latency (PWLs), as measured by the Von Frey test and Hargreaves test in adult mice. …”

Image 1_Microglial adenosine A2A receptor in the paraventricular thalamic nucleus regulates pain sensation and analgesic effects independent of opioid and cannabinoid receptors.tif by Yiping Cao (1229856)

“…Pharmacological activation of local PVT A_2AR with its agonist CGS21680 induced significantly decreased 50% paw withdrawal threshold (50%PWTs) and paw withdrawal latency (PWLs), as measured by the Von Frey test and Hargreaves test in adult mice. …”

Image 2_Microglial adenosine A2A receptor in the paraventricular thalamic nucleus regulates pain sensation and analgesic effects independent of opioid and cannabinoid receptors.tif by Yiping Cao (1229856)

“…Pharmacological activation of local PVT A_2AR with its agonist CGS21680 induced significantly decreased 50% paw withdrawal threshold (50%PWTs) and paw withdrawal latency (PWLs), as measured by the Von Frey test and Hargreaves test in adult mice. …”

Inpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Outpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)